Statistics from Altmetric.com
Intermittent claudication (IC) is a common condition that may be associated with significant disability and reduction in quality of life. Pharmacological options for the treatment of the symptoms of this condition are very limited. Naftidrofuryl oxalate is recommended in the National Institute for Health and Care Excellence (NICE) guidelines,1 and while this has been shown to improve pain-free and maximal walking distances, its effect, if any, on quality of life is unknown. ACE inhibitors (ACEI) are believed to have the potential to improve blood flow, endothelial function, and alter muscle metabolism and structure. Previous small studies involving ACEI have shown …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.